Etanercept
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Etanercept: From Rheumatoid Arthritis and Spondyloarthritis to Rheumatoid Vasculitis
One-Sentence Summary
Etanercept is a TNF-blocking fusion protein, originally used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. The TxGNN model predicts it may be effective for rheumatoid vasculitis (top-ranked prediction), but this prediction has only 1 clinical trial (which does not test etanercept for this condition) and 20 publications, several of which report etanercept causing vasculitis. Evidence for this top prediction is weak. Other predictions (inflammatory spondylopathy, polyarticular JIA) are much better supported, but they largely overlap with already-approved uses.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis (from the knowledge graph; Singapore licence indication text is not available) |
| Predicted New Indication | Rheumatoid vasculitis |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on known information, etanercept is a soluble TNF receptor–Fc fusion protein that binds TNF-alpha and blocks its inflammatory activity. Its efficacy in rheumatoid arthritis is well established.
Rheumatoid vasculitis is a severe extra-articular complication of rheumatoid arthritis, so TNF blockade is mechanistically plausible. However, the literature also contains reports of etanercept-associated cutaneous vasculitis, leukocytoclastic vasculitis and nephropathy. This suggests etanercept may paradoxically induce vasculitis in some patients, which weakens the therapeutic hypothesis.
The only listed trial concerns perioperative immunosuppressant management in rheumatology patients and does not test etanercept against rheumatoid vasculitis. A systematic review of biological therapy in rheumatoid vasculitis exists, but the data compiled for this report do not show etanercept-specific efficacy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Recruiting | 80 | Compares stopping immunosuppressants for different durations before shoulder replacement in rheumatology patients; addresses perioperative drug handling, not etanercept efficacy in vasculitis |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33058033 | 2021 | Systematic Review | Clin Rheumatol | Systematic review (PRISMA) of biological drugs in rheumatoid vasculitis, a severe extra-articular RA manifestation |
| 28391344 | 2017 | Review | Nephrol Dial Transplant | Discusses the role of TNFα blockade in ANCA-associated vasculitis and glomerulonephritis |
| 16624928 | 2006 | Review | J Am Soc Nephrol | Examines TNF-alpha in ANCA-associated vasculitis, drawing lessons from other chronic inflammatory diseases |
| 15853915 | 2005 | Review | Scand J Immunol | Immunology of cutaneous vasculitis associated with etanercept and infliximab |
| 28123776 | 2017 | Cohort (BSRBR-RA) | RMD Open | Compares lupus-like and vasculitis-like events in TNFi-treated vs. non-biological DMARD-treated RA patients |
| 31632872 | 2019 | Case Report | Cureus | Etanercept-associated nephropathy |
| 10955351 | 2000 | Case Report | J Rheumatol | First reported case of leukocytoclastic vasculitis due to etanercept in severe RA |
| 12209493 | 2002 | Case Report | Arthritis Rheum | Accelerated nodulosis and vasculitis following etanercept for RA |
| 25544845 | 2014 | Case Report | Case Rep Med | Large vessel vasculitis in an RA patient on anti-TNF therapy |
| 19648728 | 2009 | Case Report | Dermatology | Disseminated herpes zoster mimicking rheumatoid vasculitis in an RA patient on etanercept |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14440P | Enbrel Solution for Injection in a Pre-filled Pen 50mg | Injection, solution | Not available |
| SIN13834P | Enbrel Solution for Injection in a Pre-Filled Syringe 25mg | Injection, solution | Not available |
| SIN13835P | Enbrel Solution for Injection in a Pre-filled Syringe 50mg | Injection, solution | Not available |
| SIN16532P | Nepexto Solution for Injection in Pre-filled Syringe 50 mg/ml | Injection, solution | Not available |
| SIN16533P | Nepexto Solution for Injection in Pre-filled Pen 50mg/ml | Injection, solution | Not available |
Two further licences are also valid: SIN16531P (Nepexto 25 mg/0.5 ml pre-filled syringe) and SIN11854P (Enbrel for Injection 25 mg/vial). All 7 are single-ingredient products with valid status.
Safety Considerations
- Drug Interactions: 100 interactions were identified. The major ones involve corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, triamcinolone, budesonide). Other major interactions include deferiprone and radiopharmaceuticals/radioimmunotherapies (iobenguane I-131, ibritumomab tiuxetan, tositumomab). Moderate interactions include metronidazole, tinidazole, rosuvastatin and simvastatin. Zinc salts are minor.
- Class safety concerns from the literature: TNF inhibitors carry risks of infection (including tuberculosis reactivation and herpes zoster), possible malignancy, and paradoxical autoimmune events such as vasculitis, nodulosis and nephropathy.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: No trial tests etanercept in rheumatoid vasculitis, and the literature includes multiple reports of etanercept causing vasculitis and nodulosis. The high TxGNN score is not backed by direct evidence, and the safety signal runs against the hypothesis.
Other predictions from the model (for context):
- Inflammatory spondylopathy (99.57%, L1, Proceed with Guardrails): overlaps with approved ankylosing spondylitis and axial spondyloarthritis uses, supported by Phase 3 RCTs (e.g., NCT00421915, NCT00434044, NCT00317499). It is effectively an existing indication, not true repurposing.
- Polyarticular juvenile rheumatoid arthritis (99.50%, L1, Proceed with Guardrails): an approved JIA use with Phase 3 data. Guardrails are standard paediatric TNF-inhibitor monitoring.
- Juvenile chronic polyarthritis (L2) and RF-positive polyarticular JIA (L3): overlap with approved JIA use.
- Hold (L4/L5): rheumatoid nodulosis (literature indicates harm), vertebral disease (only indirect support), hypermobility of coccyx, Kummell disease and WHIM syndrome (no trials or literature, no plausible TNF mechanism).
To proceed, the following is needed:
- Etanercept-specific efficacy and safety data in rheumatoid vasculitis (e.g., a controlled trial or well-designed cohort), with attention to paradoxical vasculitis risk
- The package insert warnings, contraindications and approved-indication text from the Singapore licences
- Detailed mechanism of action data
- Clarification of whether the better-supported predictions (spondyloarthritis, JIA) are already covered by existing Singapore labelling, since they would then not be new indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.